CHU Sart Tilman
Liège, Liege, 4000, Belgium
NCT Number: NCT00504803
Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning from HLA-mismatched PBSC or cord blood: a Pilot Study
Looking for future studies?
Notify MeUp to 75 year
All sexes
Interventional
Phase 2
Liège, Liege, 4000, Belgium
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
V.1. Patients
V.1.1. Diseases
Hematological malignancies confirmed histologically and not rapidly progressing:
V.1.2. Clinical situations
V.1.3. Other inclusion criteria
V.1.4. Exclusion criteria
V.2. PBSC donors
V.2.1. Inclusion criteria
V.2.2. Exclusion criteria
V.2.3. HLA matching
Related or unrelated donors who have 1-2 HLA mismatches, as either :
V.3. Cord blood unit
Banked cord blood units will be used if they fulfill the following criteria:
Infusion of mesenchymal stem cells on the same day as hematopoietic stem cell infusion.
Other names: Mesenchymal stem cells
Time frame: 100 days
Time frame: 365 days
University of Liege
Other
Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning: a Pilot Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01349101
Graft vs Host Disease, Hematologic Diseases
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT00886522
Graft vs Host Disease, Hematologic Diseases
Bologna, Italy
View Trial DetailsNCT06799195
Graft vs Host Disease, Graft-versus-host Disease (GVHD)
Omaha, Nebraska, United States
View Trial DetailsNCT06179511
Hematologic Diseases, Hematologic Neoplasms
Duarte, California, United States
View Trial Details